MEDPLUS Medplus Health Services Q4 FY26 results (Jan–Mar 2026) and concall
Medplus Health reported a strong Q4 FY26, driven by robust pharmacy revenue growth and healthy SSSG for mature stores. The company continued its aggressive store expansion, adding 218 net new stores in the quarter, and clarified its zero-debt status. While private label growth is expected to resume, management acknowledged store closures and the inherent inventory risk for private label products.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 22.8%, net profit up 21.4% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 156 | 177 | 202 | 184 | 206 +32% | 223 +26% | 248 +23% |
| EBITDA | 17 | 19 | 24 | 24 | 27 +59% | 29 +53% | 27 +13% |
| Net profit | 8 | 9 | 14 | 14 | 16 +100% | 17 +89% | 17 +21% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
